Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cytotherapy. 2016 Feb;18(2):151-9. doi: 10.1016/j.jcyt.2015.11.008. Epub 2015 Dec 23.

International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials.

Author information

  • 1Department of Hematology and Medical Oncology, Winship Cancer Institute, and Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: jgalipe@emory.edu.
  • 2Section of Hematology, Stem Cell Research Laboratory and Cell Factory, Department of Medicine, University of Verona, Verona, Italy.
  • 3Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
  • 4Regenerative and Heamatological Medicine, King's College London, London, UK.
  • 5Regenerative Medicine, Athersys Inc., Cleveland, OH, USA.
  • 6School of Engineering and Materials Science, Queen Mary University of London, London, UK.
  • 7Department of Medical and Surgical Sciences for Children and Adults, Division of Oncology, University-Hospital of Modena and Reggio Emilia, Modena, Italy.
  • 8Department of Immunohematology and Bloodtransfusion, Leiden University Medical Centre, Leiden, Netherlands.
  • 9Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Texas Children's Hospital, Houston, TX, USA.
  • 10Center for Stem Cell Research and Regenerative Medicine, Department of Medicine, and Department of Surgery, Tulane University School of Medicine, New Orleans, LA, USA.
  • 11Department of Medicine, University of Wisconsin-Madison, School of Medicine and Public Health, and University of Wisconsin Carbone Cancer Center, Madison, WI, USA.
  • 12Department of Haematology, St George's Hospital and Medical School, London, UK; Blood Services Group, Health Sciences Authority, Singapore.
  • 13Division of Clinical Immunology and Transfusion Medicine, Karolinska Institutet, Stockholm, Sweden.
  • 14Department of Biomedicine, University Hospital Basel, Basel, Switzerland.
  • 15Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
  • 16Mesoblast Inc., New York, NY, USA.
  • 17Stem Cell Group, Bioprocessing Technology Institute, Agency for Science Technology and Research (A*STAR), Singapore.
  • 18Division of Occupational and Environmental Health Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
  • 19Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL, USA.
  • 20IFR150 STROMALab UMR 5273 UPS-CNRS-EFS-INSERM U1031, Toulouse, France.
  • 21Institute of Health Sciences, Chinese Academy of Sciences, Shanghai, China; The First Affiliated Hospital, Soochow University Institutes for Translational Medicine, Suzhou, China.
  • 22Cell Processing Section, Department of Transfusion Medicine Clinical Center, NIH, Bethesda, MD, USA.
  • 23Cell Therapy Program, University Health Network, Toronto, Canada.
  • 24Department of Medicine, University of Vermont College of Medicine, Burlington, VT, USA.
  • 25UMR5273 STROMALab CNRS/EFS/UPS-INSERM U1031, Toulouse, France.

Abstract

Mesenchymal stromal cells (MSCs) as a pharmaceutical for ailments characterized by pathogenic autoimmune, alloimmune and inflammatory processes now cover the spectrum of early- to late-phase clinical trials in both industry and academic sponsored studies. There is a broad consensus that despite different tissue sourcing and varied culture expansion protocols, human MSC-like cell products likely share fundamental mechanisms of action mediating their anti-inflammatory and tissue repair functionalities. Identification of functional markers of potency and reduction to practice of standardized, easily deployable methods of measurements of such would benefit the field. This would satisfy both mechanistic research as well as development of release potency assays to meet Regulatory Authority requirements for conduct of advanced clinical studies and their eventual registration. In response to this unmet need, the International Society for Cellular Therapy (ISCT) addressed the issue at an international workshop in May 2015 as part of the 21st ISCT annual meeting in Las Vegas. The scope of the workshop was focused on discussing potency assays germane to immunomodulation by MSC-like products in clinical indications targeting immune disorders. We here provide consensus perspective arising from this forum. We propose that focused analysis of selected MSC markers robustly deployed by in vitro licensing and metricized with a matrix of assays should be responsive to requirements from Regulatory Authorities. Workshop participants identified three preferred analytic methods that could inform a matrix assay approach: quantitative RNA analysis of selected gene products; flow cytometry analysis of functionally relevant surface markers and protein-based assay of secretome. We also advocate that potency assays acceptable to the Regulatory Authorities be rendered publicly accessible in an "open-access" manner, such as through publication or database collection.

Copyright © 2015 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

KEYWORDS:

ISCT; Mesenchymal Stromal cells; clinical trials; immune functional testing; matrix assays; potency assays; release assays

PMID:
26724220
[PubMed - in process]
PMCID:
PMC4745114
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk